TRAWS PHARMA INC (TRAW)
US68232V8019 - Common Stock
Overall TRAW gets a fundamental rating of 1 out of 10. We evaluated TRAW against 193 industry peers in the Pharmaceuticals industry. TRAW may be in some trouble as it scores bad on both profitability and health. TRAW is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
TRAW had negative earnings in the past year.
In the past year TRAW has reported a negative cash flow from operations.
TRAW had negative earnings in each of the past 5 years.
TRAW had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -1575.48%, TRAW is not doing good in the industry: 98.43% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1575.48% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-53.61%
ROA(5y)N/A
ROE(3y)-93.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for TRAW so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TRAW does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TRAW has been increased compared to 1 year ago.
TRAW has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
TRAW has an Altman-Z score of -104.93. This is a bad value and indicates that TRAW is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -104.93, TRAW is doing worse than 95.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -104.93 |
ROIC/WACCN/A
WACC9.6%
2.3 Liquidity
A Current Ratio of 1.07 indicates that TRAW should not have too much problems paying its short term obligations.
TRAW has a worse Current ratio (1.07) than 83.77% of its industry peers.
A Quick Ratio of 1.07 indicates that TRAW should not have too much problems paying its short term obligations.
The Quick ratio of TRAW (1.07) is worse than 77.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.07 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 1.10% over the past year.
Looking at the last year, TRAW shows a decrease in Revenue. The Revenue has decreased by 0.00% in the last year.
EPS 1Y (TTM)1.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3730.43%
Revenue 1Y (TTM)0%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0%
3.2 Future
The Earnings Per Share is expected to grow by 2.66% on average over the next years.
TRAW is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.69% yearly.
EPS Next Y-16446.67%
EPS Next 2Y-518.47%
EPS Next 3Y2.66%
EPS Next 5YN/A
Revenue Next Year6.81%
Revenue Next 2Y3.35%
Revenue Next 3Y11.69%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
TRAW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TRAW is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-518.47%
EPS Next 3Y2.66%
5. Dividend
5.1 Amount
No dividends for TRAW!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TRAWS PHARMA INC
NASDAQ:TRAW (12/20/2024, 8:00:01 PM)
After market: 5.02 0 (0%)5.02
-0.31 (-5.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners100.68%
Inst Owner ChangeN/A
Ins Owners27.01%
Ins Owner Change-0.07%
Market Cap15.21M
Analysts82.86
Price Target153 (2947.81%)
Short Float %0.36%
Short Ratio0.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.26%
Min Revenue beat(2)-6.86%
Max Revenue beat(2)-3.65%
Revenue beat(4)0
Avg Revenue beat(4)-8.74%
Min Revenue beat(4)-15.96%
Max Revenue beat(4)-3.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.69%
PT rev (3m)2207.69%
EPS NQ rev (1m)-2313.79%
EPS NQ rev (3m)-2313.79%
EPS NY rev (1m)-2.46%
EPS NY rev (3m)-2461.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.88%
Revenue NY rev (3m)0.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 67.3 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.9
EYN/A
EPS(NY)-34.42
Fwd EYN/A
FCF(TTM)-9.96
FCFYN/A
OCF(TTM)-9.96
OCFYN/A
SpS0.07
BVpS-0.67
TBVpS-0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1575.48% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-53.61%
ROA(5y)N/A
ROE(3y)-93.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.07 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | -104.93 |
F-Score3
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3730.43%
EPS Next Y-16446.67%
EPS Next 2Y-518.47%
EPS Next 3Y2.66%
EPS Next 5YN/A
Revenue 1Y (TTM)0%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0%
Revenue Next Year6.81%
Revenue Next 2Y3.35%
Revenue Next 3Y11.69%
Revenue Next 5YN/A
EBIT growth 1Y-3.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.72%
EBIT Next 3Y-16.08%
EBIT Next 5YN/A
FCF growth 1Y-10.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.05%
OCF growth 3YN/A
OCF growth 5YN/A